파브리병 치료제 시장 규모는 향후 수년간 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 8.8%의 연평균 복합 성장률(CAGR)로 32억 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 이 질환의 유병률 증가, 인지도 및 진단율 증가, 의료 인프라 확대, 희귀질환 연구에 대한 투자 증가, 환자 인식 증가, 상환 정책 확대에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 유전자 치료의 발전, 효소 보충 요법의 발전, 진단 기술의 발전, 새로운 치료법의 발전, 환자 관리를 위한 디지털 헬스 기술의 통합 등을 꼽을 수 있습니다.
파브리병 치료제 시장의 성장은 신장질환의 유병률 증가에 의해 주도될 것으로 예상됩니다. 신장질환(신장병)은 신장 기능에 영향을 미치는 병태를 포함하며, 유전적 요인, 생활습관 선택, 환경적 영향, 기저 건강 문제 등으로 인해 증가 추세에 있습니다. 파브리병은 특히 신장 세포내 글로봇리아오실세라미드(Gb3)의 축적에 의해 발생하여 신장 손상과 기능 장애를 초래합니다. 이는 신장 관련 합병증을 예방하기 위해 조기 발견과 개입이 시급히 필요하다는 것을 강조합니다. 예를 들어 호주 통계청의 최근 자료에 따르면 지난 10년간 신장질환 환자가 0.2% 증가하여 2022년에는 24만 6,200명(인구의 1.0%)이 신장질환 유병률 증가와 파브리병 치료 시장에 미치는 영향을 강조하고 있습니다.
파브리병 치료제 시장의 주요 업체들은 혁신적이고 지속가능한 방법을 통해 치료 효과를 높이고 비용을 절감하며 환자 결과를 개선하기 위해 식물 세포 기반 치료법을 적극적으로 개발하고 있습니다. 파브리병에 대한 식물 세포 기반 치료는 파브리병 환자에게서 발견되는 결핍된 효소를 생산하기 위해 식물 세포를 사용하는 것을 포함합니다. 이러한 식물 유래 효소는 체내 결핍 또는 결손된 효소를 보충하는 치료 옵션으로 작용하여 증상을 완화하고 환자의 전반적인 건강을 개선하는 것을 목표로 합니다. 예를 들어 Chiesi Global Rare Diseases와 Protalix BioTherapeutics가 개발한 효소 보충 요법인 ELFABRIO는 2023년 5월에 승인되었습니다. 엘파브리오는 식물 세포배양에서 생산된 재조합 인간 a-갈락토시다아제 A 효소를 이용하며, 반감기를 크게 연장하기 위해 PEG로 변형되었습니다. 이 혁신적인 치료법은 치료 횟수를 줄이고, 편의성을 높이고, 증상 관리를 개선하고, 궁극적으로 파브리병 환자의 삶의 질을 향상시킬 수 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 파브리병 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 파브리병 치료 시장 : 성장률 분석
- 세계의 파브리병 치료 시장 실적 : 규모와 성장, 2019-2024
- 세계의 파브리병 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 파브리병 치료 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 파브리병 치료 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 기재 환원 요법
- 효소 보충 요법
- 샤프롱 치료
- 기타 치료법
- 세계의 파브리병 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 경로
- 정맥내 투여
- 세계의 파브리병 치료 시장 : 질병 중증도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 고전적 파브리병
- 만발성 파브리병
- 세계의 파브리병 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원 약국
- 소매 약국
- 온라인 약국
- 세계의 파브리병 치료 시장, 기재 환원 요법의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- Migalastat Hydrochloride(Galafold)
- 기타 기재 환원 요법
- 세계의 파브리병 치료 시장 효소 보충 요법의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- Agalsidase Beta(Fabrazyme)
- Agalsidase Alfa(Replagal)
- 기타 효소 보충 요법
- 세계의 파브리병 치료 시장, 샤프롱 치료의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- Migalastat Hydrochloride(Galafold)
- 세계의 파브리병 치료 시장, 기타 치료법의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 유전자 치료
- 치료
제7장 지역별·국가별 분석
- 세계의 파브리병 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 파브리병 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 파브리병 치료 시장 : 경쟁 구도
- 파브리병 치료 시장 : 기업 개요
- Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- GSK plc Overview, Products and Services, Strategy and Financial Analysis
- Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- CHIESI Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis
- Ultragenyx Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- Amicus Therapeutics Inc.
- JCR Pharmaceuticals Co. Ltd.
- Sangamo Therapeutics Inc.
- Idorsia Pharmaceuticals Ltd.
- Centogene N.V.
- Protalix BioTherapeutics
- Avrobio Inc.
- ISU Abxis
- Synageva BioPharma Corp.
- Greenovation Biotech GmbH
- CANbridge Pharmaceuticals
- Freeline
- 4D Molecular Therapeutics
- Abeona Therapeutics Inc.
- GC Biopharma Corporation
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 파브리병 치료 시장 2029 : 새로운 기회를 제공하는 국가
- 파브리병 치료 시장 2029 : 새로운 기회를 제공하는 부문
- 파브리병 치료 시장 2029 : 성장 전략
제36장 부록
KSA
Fabry disease stems from a deficiency in alpha-galactosidase A, an enzyme crucial for breaking down globotriaosylceramide (Gb3 or GL-3) fat. This results in Gb3 accumulation within cells, prompting symptoms such as pain, kidney issues, heart complications, and strokes. Treatment aims to curtail Gb3 buildup, manage symptoms, slow organ damage, and enhance patients' quality of life.
The fabry disease treatment landscape includes substrate reduction therapy, enzyme replacement therapy, chaperone interventions, among others. Substrate reduction therapy (SRT) targets the reduction of specific substances in the body linked to fabry disease. These therapies can be administered orally or intravenously and cater to varying disease severities such as classic and late-onset fabry disease. Distribution channels encompass hospital, retail, and online pharmacies.
The fabry disease treatment market research report is one of a series of new reports from The Business Research Company that provides fabry disease treatment market statistics, including the fabry disease treatment industry global market size, regional shares, competitors with fabry disease treatment market share, detailed fabry disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the fabry disease treatment industry. These fabry disease treatment market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The fabry disease treatment market size has grown strongly in recent years. It will grow from $2.09 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing awareness and diagnosis rates, increasing adoption of enzyme replacement therapies, increasing use of chaperone therapies, increasing healthcare infrastructure, rise in investment in rare disease research, increasing population, and increasing regulatory incentives for orphan drugs.
The fabry disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing prevalence of the disease, rising awareness and diagnosis rates, expanding healthcare infrastructure, growing investment in rare disease research, growing patient awareness, and expanding reimbursement policies. Major trends in the forecast period include advancements in gene therapy, advancements in enzyme replacement therapies, advancements in diagnostic techniques, advancements in novel therapies, and integration of digital health technologies for patient management.
The growth of the Fabry disease treatment market is expected to be driven by the increasing prevalence of renal diseases. Renal diseases, or kidney diseases, encompass conditions that affect kidney function and are on the rise due to genetic factors, lifestyle choices, environmental influences, and underlying health issues. Fabry disease, specifically caused by the buildup of globotriaosylceramide (Gb3) in kidney cells, results in kidney damage and dysfunction. This emphasizes the urgent need for early detection and intervention to prevent kidney-related complications. For instance, recent data from the Australian Bureau of Statistics revealed a 0.2% increase in kidney disease cases over the past decade, with 246,200 people (1.0% of the population) affected in 2022, highlighting the escalating prevalence of renal diseases and their impact on the fabry disease treatment market.
Key players in the Fabry disease treatment market are actively developing plant cell-based therapies to enhance treatment efficacy, reduce costs, and improve patient outcomes through innovative and sustainable methods. Plant cell-based treatments for fabry disease involve using plant cells to produce deficient enzymes found in individuals with fabry disease. These plant-derived enzymes serve as a therapeutic option to replace the missing or defective enzymes in the body, aiming to alleviate symptoms and enhance patients' overall health. For example, ELFABRIO, an enzyme replacement therapy developed by Chiesi Global Rare Diseases and Protalix BioTherapeutics Inc., was approved in May 2023. ELFABRIO utilizes recombinant human a-Galactosidase-A enzyme produced in plant-cell culture and modified with PEGylation to extend its half-life significantly. This innovative treatment approach reduces treatment frequency, increases convenience, and improves symptom management, ultimately enhancing the quality of life for fabry disease patients.
In March 2024, CENTOGENE extended its partnership with Takeda Pharmaceutical Company Limited, a leader in developing therapies for lysosomal storage disorders (LSDs) such as fabry disease. This collaboration ensures continued access to diagnostic testing for patients globally, improving patient access to rapid and accurate diagnostics for LSDs, including fabry disease.
Major companies operating in the fabry disease treatment market are Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, CHIESI Farmaceutici S.p.A., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, Avrobio Inc., ISU Abxis, Synageva BioPharma Corp., Greenovation Biotech GmbH, CANbridge Pharmaceuticals, Freeline, 4D Molecular Therapeutics, Abeona Therapeutics Inc., GC Biopharma Corporation
North America was the largest region in the fabry disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the fabry disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The fabry disease treatment market consists of revenues earned by entities by providing services such as diagnosis and screening, enzyme replacement therapy, gene therapy, disease management programs, and patient education and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The Fabry disease treatment market also includes sales of Agalsidase alfa, Agalsidase beta, and Migalastat. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Fabry Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on fabry disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for fabry disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fabry disease treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Substrate Reduction Therapy; Enzyme Replacement Therapy; Chaperone Treatment; Other Treatments
- 2) By Route Of Administration: Oral Route; Intravenous Route
- 3) By Disease Severity: Classic Fabry Disease; Late-Onset Fabry Disease
- 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- Subsegments:
- 1) By Substrate Reduction Therapy: Migalastat Hydrochloride (Galafold); Other Substrate Reduction Therapies
- 2) By Enzyme Replacement Therapy: Agalsidase Beta (Fabrazyme); Agalsidase Alfa (Replagal); Other Enzyme Replacement Therapies
- 3) By Chaperone Treatment: Migalastat Hydrochloride (Galafold)
- 4) By Other Treatments: Gene Therapy; Symptomatic Treatment
- Companies Mentioned: Sanofi S.A.; GSK plc; Takeda Pharmaceutical Company Limited; CHIESI Farmaceutici S.p.A.; Ultragenyx Pharmaceutical Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Fabry Disease Treatment Market Characteristics
3. Fabry Disease Treatment Market Trends And Strategies
4. Fabry Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Fabry Disease Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Fabry Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Fabry Disease Treatment Market Growth Rate Analysis
- 5.4. Global Fabry Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Fabry Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Fabry Disease Treatment Total Addressable Market (TAM)
6. Fabry Disease Treatment Market Segmentation
- 6.1. Global Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Substrate Reduction Therapy
- Enzyme Replacement Therapy
- Chaperone Treatment
- Other Treatments
- 6.2. Global Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Route
- Intravenous Route
- 6.3. Global Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Classic Fabry Disease
- Late-Onset Fabry Disease
- 6.4. Global Fabry Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.5. Global Fabry Disease Treatment Market, Sub-Segmentation Of Substrate Reduction Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Migalastat Hydrochloride (Galafold)
- Other Substrate Reduction Therapies
- 6.6. Global Fabry Disease Treatment Market, Sub-Segmentation Of Enzyme Replacement Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Agalsidase Beta (Fabrazyme)
- Agalsidase Alfa (Replagal)
- Other Enzyme Replacement Therapies
- 6.7. Global Fabry Disease Treatment Market, Sub-Segmentation Of Chaperone Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Migalastat Hydrochloride (Galafold)
- 6.8. Global Fabry Disease Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gene Therapy
- Symptomatic Treatment
7. Fabry Disease Treatment Market Regional And Country Analysis
- 7.1. Global Fabry Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Fabry Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Fabry Disease Treatment Market
- 8.1. Asia-Pacific Fabry Disease Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Fabry Disease Treatment Market
- 9.1. China Fabry Disease Treatment Market Overview
- 9.2. China Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Fabry Disease Treatment Market
- 10.1. India Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Fabry Disease Treatment Market
- 11.1. Japan Fabry Disease Treatment Market Overview
- 11.2. Japan Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Fabry Disease Treatment Market
- 12.1. Australia Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Fabry Disease Treatment Market
- 13.1. Indonesia Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Fabry Disease Treatment Market
- 14.1. South Korea Fabry Disease Treatment Market Overview
- 14.2. South Korea Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Fabry Disease Treatment Market
- 15.1. Western Europe Fabry Disease Treatment Market Overview
- 15.2. Western Europe Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Fabry Disease Treatment Market
- 16.1. UK Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Fabry Disease Treatment Market
- 17.1. Germany Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Fabry Disease Treatment Market
- 18.1. France Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Fabry Disease Treatment Market
- 19.1. Italy Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Fabry Disease Treatment Market
- 20.1. Spain Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Fabry Disease Treatment Market
- 21.1. Eastern Europe Fabry Disease Treatment Market Overview
- 21.2. Eastern Europe Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Fabry Disease Treatment Market
- 22.1. Russia Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Fabry Disease Treatment Market
- 23.1. North America Fabry Disease Treatment Market Overview
- 23.2. North America Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Fabry Disease Treatment Market
- 24.1. USA Fabry Disease Treatment Market Overview
- 24.2. USA Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Fabry Disease Treatment Market
- 25.1. Canada Fabry Disease Treatment Market Overview
- 25.2. Canada Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Fabry Disease Treatment Market
- 26.1. South America Fabry Disease Treatment Market Overview
- 26.2. South America Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Fabry Disease Treatment Market
- 27.1. Brazil Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Fabry Disease Treatment Market
- 28.1. Middle East Fabry Disease Treatment Market Overview
- 28.2. Middle East Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Fabry Disease Treatment Market
- 29.1. Africa Fabry Disease Treatment Market Overview
- 29.2. Africa Fabry Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Fabry Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Fabry Disease Treatment Market, Segmentation By Disease Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Fabry Disease Treatment Market Competitive Landscape And Company Profiles
- 30.1. Fabry Disease Treatment Market Competitive Landscape
- 30.2. Fabry Disease Treatment Market Company Profiles
- 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GSK plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. CHIESI Farmaceutici S.p.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Ultragenyx Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Fabry Disease Treatment Market Other Major And Innovative Companies
- 31.1. Amicus Therapeutics Inc.
- 31.2. JCR Pharmaceuticals Co. Ltd.
- 31.3. Sangamo Therapeutics Inc.
- 31.4. Idorsia Pharmaceuticals Ltd.
- 31.5. Centogene N.V.
- 31.6. Protalix BioTherapeutics
- 31.7. Avrobio Inc.
- 31.8. ISU Abxis
- 31.9. Synageva BioPharma Corp.
- 31.10. Greenovation Biotech GmbH
- 31.11. CANbridge Pharmaceuticals
- 31.12. Freeline
- 31.13. 4D Molecular Therapeutics
- 31.14. Abeona Therapeutics Inc.
- 31.15. GC Biopharma Corporation
32. Global Fabry Disease Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Fabry Disease Treatment Market
34. Recent Developments In The Fabry Disease Treatment Market
35. Fabry Disease Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Fabry Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Fabry Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Fabry Disease Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
